Evidence map›Paper›PMID 40415200›Full record

ArticleMolecular biology and evolution2025

Nonhypermutator Cancers Access Driver Mutations Through Reversals in Germline Mutational Bias.

Marwa Z Tuffaha, David Castellano, Claudia Serrano Colomé, Ryan N Gutenkunst, Lindi M Wahl

Abstract read
In one paragraph

Article in Molecular biology and evolution, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Marwa Z TuffahaMathematics, Western University, London, ON, Canada N6A 5B7.ORCID 0000-0002-6285-0938
David CastellanoDepartment of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.ORCID 0000-0001-8778-6007
Claudia Serrano ColoméCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Dr. Aiguader 88, Barcelona 08003, Spain.ORCID 0000-0003-2043-8264
Ryan N GutenkunstDepartment of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85721, USA.ORCID 0000-0002-8659-0579
Lindi M WahlMathematics, Western University, London, ON, Canada N6A 5B7.ORCID 0000-0003-1163-0940

Funding

Joint inferences of natural selection between sites and populationsR01GM127348 · NIGMS · UNIVERSITY OF ARIZONA · PI GUTENKUNST, RYAN · 2019 to 2023
$1.7M
Population genomic inferences of history and selection across populations and timeR35GM149235 · NIGMS · UNIVERSITY OF ARIZONA · PI Ryan Gutenkunst · 2023 to 2026
$1.3M
Centro de Excelencia Severo Ochoa CEX2020-001049-SNatural Sciences and Engineering Research Council of Canada RGPIN-2019-06294NIGMS NIH HHS R01 GM127348NIGMS NIH HHS R01GM127348 and R35GM149235NIGMS NIH HHS R35 GM149235
6 · The paper itself

Abstract

Cancer is an evolutionary disease driven by mutations in asexually reproducing somatic cells. In asexual microbes, bias reversals in the mutation spectrum can speed adaptation by increasing access to previously undersampled beneficial mutations. By analyzing tumors from 20 tissues, along with normal tissue and the germline, we demonstrate this effect in cancer. Nonhypermutated tumors reverse the germline mutation bias and have consistent spectra across tissues. These spectra changes carry the signature of hypoxia, and they facilitate positive selection in cancer genes. Hypermutated and nonhypermutated tumors thus acquire driver mutations differently: hypermutated tumors by higher mutation rates and nonhypermutated tumors by changing the mutation spectrum to reverse the germline mutation bias.

Indexed as

Germ-Line MutationNeoplasmsHumansMutation Ratecancerhypermutatorhypoxiamutation biasmutation spectrumpositive selection

Identifiers

PMID40415200
PMCPMC12104016

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.